JP2005530736A5 - - Google Patents

Download PDF

Info

Publication number
JP2005530736A5
JP2005530736A5 JP2003585730A JP2003585730A JP2005530736A5 JP 2005530736 A5 JP2005530736 A5 JP 2005530736A5 JP 2003585730 A JP2003585730 A JP 2003585730A JP 2003585730 A JP2003585730 A JP 2003585730A JP 2005530736 A5 JP2005530736 A5 JP 2005530736A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
optionally substituted
amount
beta blocker
esmolol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003585730A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005530736A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2003/012043 external-priority patent/WO2003088978A1/en
Publication of JP2005530736A publication Critical patent/JP2005530736A/ja
Publication of JP2005530736A5 publication Critical patent/JP2005530736A5/ja
Pending legal-status Critical Current

Links

JP2003585730A 2002-04-18 2003-04-18 ベーターブロッカー、カルシウムチャネルブロッカー、または心臓のグリコシドと共にa1アデノシンアゴニストを投与することを含む不整脈の処置方法 Pending JP2005530736A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37376602P 2002-04-18 2002-04-18
PCT/US2003/012043 WO2003088978A1 (en) 2002-04-18 2003-04-18 Method of treating arrhythmias comprising administration of an a1 adenosine agonist with a beta blocker, calcium channel blocker or a cardiac glycoside

Publications (2)

Publication Number Publication Date
JP2005530736A JP2005530736A (ja) 2005-10-13
JP2005530736A5 true JP2005530736A5 (https=) 2006-06-01

Family

ID=29251078

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003585730A Pending JP2005530736A (ja) 2002-04-18 2003-04-18 ベーターブロッカー、カルシウムチャネルブロッカー、または心臓のグリコシドと共にa1アデノシンアゴニストを投与することを含む不整脈の処置方法

Country Status (17)

Country Link
US (3) US7005425B2 (https=)
EP (1) EP1494685B1 (https=)
JP (1) JP2005530736A (https=)
KR (1) KR20040106354A (https=)
CN (2) CN101385738A (https=)
AT (1) ATE418991T1 (https=)
AU (1) AU2003235466C1 (https=)
CA (1) CA2482928A1 (https=)
DE (1) DE60325572D1 (https=)
ES (1) ES2318129T3 (https=)
IL (1) IL164652A0 (https=)
MX (1) MXPA04010285A (https=)
NO (1) NO20045005L (https=)
NZ (1) NZ536001A (https=)
RU (1) RU2332220C2 (https=)
WO (1) WO2003088978A1 (https=)
ZA (1) ZA200408411B (https=)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1168912B1 (en) 1999-03-23 2007-05-09 Hibernation Therapeutics Limited Organ arrest, protection and preservation
US6403567B1 (en) 1999-06-22 2002-06-11 Cv Therapeutics, Inc. N-pyrazole A2A adenosine receptor agonists
USRE47351E1 (en) 1999-06-22 2019-04-16 Gilead Sciences, Inc. 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists
CA2671940A1 (en) 2000-02-23 2001-08-30 Cv Therapeutics, Inc. Identification of partial agonists of the a2a adenosine receptor
US7713946B2 (en) * 2002-07-11 2010-05-11 Cv Therapeutics, Inc. Partial and full agonists A1 adenosine receptors
US7157440B2 (en) * 2001-07-13 2007-01-02 Cv Therapeutics, Inc. Partial and full agonists of A1 adenosine receptors
CN101385738A (zh) * 2002-04-18 2009-03-18 Cv医药有限公司 包括给予A1腺苷激动剂以及β受体阻滞剂、钙通道阻滞剂、或强心苷的治疗心律失常的方法
US8470801B2 (en) 2002-07-29 2013-06-25 Gilead Sciences, Inc. Myocardial perfusion imaging methods and compositions
GB2436255B (en) * 2002-12-23 2007-11-28 Global Cardiac Solutions Pty L Organ preconditioning, arrest, protection, preservation and recovery
CA2573682A1 (en) * 2004-07-12 2006-02-16 Cv Therapeutics, Inc. Process for the preparation of a1 adenosine receptor agonists
US20060019954A1 (en) * 2004-07-20 2006-01-26 Cedars-Sinai Medical Center Method for reducing the likelihood of the occurrence of cardiac arrhythmias
US7300923B2 (en) * 2004-08-30 2007-11-27 Cv Therapeutics, Inc. Partial and full agonists of A1 adenosine receptors
CA2581086C (en) 2004-09-14 2023-11-07 The Regents Of The University Of Colorado, A Body Corporate Method for treatment with bucindolol based on genetic targeting
US7822474B2 (en) * 2005-11-30 2010-10-26 Cedars-Sinai Medical Center Methods for the prediction of arrhythmias and prevention of sudden cardiac death
US7732595B2 (en) 2006-02-03 2010-06-08 Gilead Palo Alto, Inc. Process for preparing an A2A-adenosine receptor agonist and its polymorphs
JP2009538834A (ja) 2006-05-29 2009-11-12 ハイバーネイション セラピューティクス リミテッド 組織維持の改善
ES2539762T3 (es) 2006-07-25 2015-07-03 Hibernation Therapeutics, A Kf Llc Tratamiento de traumatismos
WO2008106724A1 (en) 2007-03-02 2008-09-12 Hibernation Therapeutics Limited Transplants
US20100311738A1 (en) 2007-12-21 2010-12-09 Aop Orphan Pharmaceuticals Ag Pharmaceutical Composition For The Parenteral Administration Of Ultrashort-Effective Beta-Adrenoreceptor Antagonists
AU2009296235A1 (en) * 2008-09-29 2010-04-01 Gilead Sciences, Inc. Combinations of a rate control agent and an A-2-alpha receptor antagonist for use in multidetector computed tomography methods
GB0903299D0 (en) * 2009-02-26 2009-04-08 Guys And St Thomas Nhs Foundat Composition and methods
EP3552602B1 (en) * 2009-03-18 2025-03-05 Incarda Therapeutics, Inc. Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
WO2011019752A2 (en) 2009-08-14 2011-02-17 Gilead Palo Alto, Inc. A1 adenosine receptor agonist polymorphs
SG182285A1 (en) 2010-01-11 2012-08-30 Inotek Pharmaceuticals Corp Combination, kit and method of reducing intraocular pressure
ES2613255T3 (es) * 2010-03-19 2017-05-23 Inotek Pharmaceuticals Corporation Composiciones combinadas de agonistas de adenosina A1 y bloqueadores de receptores ß-adrenérgicos no selectivos para reducir la presión intraocular
EA201290958A1 (ru) 2010-03-26 2013-04-30 Инотек Фармасьютикалз Корпорейшн Способ снижения внутриглазного давления у людей с применением n6-циклопентиладенозина (cpa), производных cpa или их пролекарств
US20120005128A1 (en) * 2010-06-29 2012-01-05 Sanofi Methods for reducing the risk of an adverse dronedarone / calcium channel blockers interaction in a patient suffering from atrial fibrilation
BR112014018413A8 (pt) 2012-01-26 2017-07-11 Inotek Pharmaceuticals Corp Polimorfos anidros de nitrato de metila [(2r,3s,4r,5r)-5-(6-(ciclopentilamino)-9h-purin-9-il)-3,4-diidroxitetraidrofuran-2-il)] e processos de preparação do mesmo
CA2903114A1 (en) 2013-03-15 2014-09-25 Inotek Pharmaceuticals Corporation Ophthalmic formulations
WO2015006831A1 (en) 2013-07-17 2015-01-22 Hts Therapeutics Pty Ltd A method for reducing, inflammation, coagulation and adhesions
WO2015089494A1 (en) * 2013-12-13 2015-06-18 Ankenman Ralph Compositions and methods for treating dysregulated systems
CN109069495A (zh) 2016-02-01 2018-12-21 英凯达治疗公司 电子监测联合吸入药理学疗法管理包括心房颤动在内的心律失常
CN106370754B (zh) * 2016-11-07 2019-03-08 西安科技大学 基于手性高效液相色谱-质谱/质谱技术定量检测布新洛尔光学异构体含量的方法
AU2018266199A1 (en) 2017-05-10 2019-11-07 Incarda Therapeutics, Inc. Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
US10744087B2 (en) 2018-03-22 2020-08-18 Incarda Therapeutics, Inc. Method to slow ventricular rate
US10799138B2 (en) 2018-04-05 2020-10-13 University Of Maryland, Baltimore Method of administering sotalol IV/switch
US10512620B1 (en) 2018-08-14 2019-12-24 AltaThera Pharmaceuticals, LLC Method of initiating and escalating sotalol hydrochloride dosing
US11610660B1 (en) 2021-08-20 2023-03-21 AltaThera Pharmaceuticals LLC Antiarrhythmic drug dosing methods, medical devices, and systems
US12396970B2 (en) 2021-08-20 2025-08-26 AltaThera Pharmaceuticals LLC Anti-arrhythmic compositions and methods
US11344518B2 (en) 2018-08-14 2022-05-31 AltaThera Pharmaceuticals LLC Method of converting atrial fibrillation to normal sinus rhythm and loading oral sotalol in a shortened time frame
US11696902B2 (en) 2018-08-14 2023-07-11 AltaThera Pharmaceuticals, LLC Method of initiating and escalating sotalol hydrochloride dosing
JP7156154B2 (ja) * 2019-04-18 2022-10-19 株式会社島津製作所 培地処理システム及び培地処理方法
AU2020323594B2 (en) 2019-08-01 2022-02-03 Incarda Therapeutics, Inc. Antiarrhythmic formulation
US11007185B2 (en) 2019-08-01 2021-05-18 Incarda Therapeutics, Inc. Antiarrhythmic formulation

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5108363A (en) * 1988-02-19 1992-04-28 Gensia Pharmaceuticals, Inc. Diagnosis, evaluation and treatment of coronary artery disease by exercise simulation using closed loop drug delivery of an exercise simulating agent beta agonist
US5736528A (en) * 1993-10-28 1998-04-07 University Of Florida Research Foundation, Inc. N6 -(epoxynorborn-2-yl) adenosines as A1 adenosine receptor agonists
AU722110B2 (en) * 1996-06-28 2000-07-20 Merck & Co., Inc. Pharmaceutical preparation
US5789416B1 (en) * 1996-08-27 1999-10-05 Cv Therapeutics Inc N6 mono heterocyclic substituted adenosine derivatives
JP2001509808A (ja) * 1997-01-31 2001-07-24 ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ 多機能性カルシウム/カルモジュリン−依存性プロテインキナーゼの阻害による不整脈の処置
CO5180581A1 (es) * 1999-09-30 2002-07-30 Pfizer Prod Inc Compuestos para el tratamiento de la isquemia ciones farmaceuticas que los contienen para el tratamiento de la isquemia
WO2001040799A2 (en) 1999-12-03 2001-06-07 Cv Therapeutics, Inc. Method of identifying partial adenosine a1 receptor agonists and their use in the treatment of arrhythmias
US6605597B1 (en) * 1999-12-03 2003-08-12 Cv Therapeutics, Inc. Partial or full A1agonists-N-6 heterocyclic 5′-thio substituted adenosine derivatives
AU9259101A (en) * 2000-09-08 2002-03-22 Cv Therapeutics Inc Purine ribosides as antiarrhythmics
US6946449B2 (en) 2001-07-13 2005-09-20 Cv Therapeutics, Inc. Partial and full agonists of A1 adenosine receptors
CN101385738A (zh) * 2002-04-18 2009-03-18 Cv医药有限公司 包括给予A1腺苷激动剂以及β受体阻滞剂、钙通道阻滞剂、或强心苷的治疗心律失常的方法

Similar Documents

Publication Publication Date Title
JP2005530736A5 (https=)
CN104470939B (zh) 用于肝脏疾病的d型氨基酸化合物
RU2004130826A (ru) Способ лечения аритмии, включающий введение агониста рецептора аденозина а1 вместе с бета-блокатором, блокатором кальциевых каналов или сердечным гликозидом
US9416154B2 (en) 5′-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
AU2012357940B2 (en) 2',4'-difluoro-2'-methyl substituted nucleoside derivatives as inhibitors of HCV RNA replication
JP4021195B2 (ja) 部分もしくは完全a1アゴニスト:n6複素環式5′−チオ置換アデノシン誘導体
CN105085592B (zh) N-[(2`r)-2`-脱氧-2`-氟-2`-甲基-p-苯基-5`-尿苷酰基]-l-丙氨酸1-甲基乙基酯及其制备方法
AU2011349278B2 (en) Cyclic nucleotide analogs
KR101320008B1 (ko) 3,5-이치환 및 3,5,7-삼치환된-3H-옥사졸로 및3H-티아졸로 〔4,5-d〕피리미딘-2-온 화합물 및 이의전구약물
KR20230170015A (ko) 항바이러스제로서의 뉴클레오시드 및 뉴클레오티드 유사체
DK2794628T3 (en) 4'-AZIDO-3'-FLUORO-SUBSTITUTED NUCLEOSIDE DERIVATIVES AS INHIBITORS OF HCV RNA REPLICATION
CN108350016B (zh) 抗病毒四氢呋喃衍生物
CN111848711A (zh) 用于hcv感染的2′-氯核苷类似物
TW201811339A (zh) 經取代之核苷、核苷酸及其類似物
TW201418274A (zh) 2’-甲基經取代之核苷衍生物及其用於治療病毒疾病之使用方法
US20140356325A1 (en) Novel 2'-c-methyl nucleoside derivative compounds
CN107108683A (zh) 用于治疗黄病毒科病毒和癌症的2’,2’‑二卤代核苷类似物
CN102089318B (zh) Hiv抑制剂化合物的盐
US20180162898A1 (en) 4'-or nucleosides for the treatment of hcv
CN106536538A (zh) 用于治疗黄病毒家族病毒和癌症的2’‑双取代核苷类似物
JP6671355B2 (ja) 呼吸器多核体ウイルスのrna複製の阻害剤としての4’‐ビニル置換ヌクレオシド誘導体
HK1048821A1 (en) Thiophene a2a receptor agonists
JP2006505525A5 (https=)
CN101240001B (zh) 2'-氟代核苷
WO2026011167A1 (en) Thionucleosides as antiviral agents